Stempoint Capital
Latest statistics and disclosures from Stempoint Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ABVX, SRRK, CNTA, SNDX, GPCR, and represent 31.33% of Stempoint Capital's stock portfolio.
- Added to shares of these 10 stocks: ABVX (+$30M), ACLX (+$21M), SRRK (+$19M), TWST (+$16M), GPCR (+$15M), TERN (+$14M), CNTA (+$10M), ADPT (+$9.9M), PALI (+$9.9M), CYTK (+$9.3M).
- Started 32 new stock positions in KTTA, EWTX, LLY, ADPT, JNJ, CAPR, APGE, EYPT, EVMN, SABS.
- Reduced shares in these 10 stocks: ROIV (-$70M), IMVT (-$30M), BHVN (-$23M), DNLI (-$22M), WVE (-$15M), CDTX (-$15M), QURE (-$12M), RVMD (-$9.8M), ARGX (-$9.2M), RZLT (-$8.6M).
- Sold out of its positions in ARKG, AKRO, ARCT, ARGX, RNA, BBIO, CGON, CDTX, CMPS, CRVS.
- Stempoint Capital was a net seller of stock by $-11M.
- Stempoint Capital has $598M in assets under management (AUM), dropping by 15.77%.
- Central Index Key (CIK): 0001952142
Tip: Access up to 7 years of quarterly data
Positions held by Stempoint Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Stempoint Capital
Stempoint Capital holds 75 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Abivax Sa Sponsored Ads (ABVX) | 8.8 | $53M | +135% | 392k | 134.85 |
|
| Scholar Rock Hldg Corp (SRRK) | 8.6 | $51M | +56% | 1.2M | 44.05 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 5.1 | $31M | +48% | 1.2M | 25.01 |
|
| Syndax Pharmaceuticals (SNDX) | 4.7 | $28M | -8% | 1.3M | 21.01 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 4.1 | $24M | +171% | 351k | 69.55 |
|
| Arcellx Common Stock (ACLX) | 3.6 | $22M | +2825% | 333k | 65.20 |
|
| Roivant Sciences SHS (ROIV) | 3.5 | $21M | -76% | 967k | 21.70 |
|
| Terns Pharmaceuticals (TERN) | 2.9 | $17M | +378% | 429k | 40.40 |
|
| Twist Bioscience Corp (TWST) | 2.7 | $16M | NEW | 518k | 31.72 |
|
| Immunovant (IMVT) | 2.7 | $16M | -64% | 645k | 25.42 |
|
| Dyne Therapeutics (DYN) | 2.7 | $16M | +75% | 835k | 19.56 |
|
| Xenon Pharmaceuticals (XENE) | 2.6 | $16M | +81% | 349k | 44.82 |
|
| Surrozen Com New (SRZN) | 2.3 | $14M | -13% | 620k | 22.60 |
|
| Celcuity (CELC) | 2.0 | $12M | -13% | 118k | 99.74 |
|
| Mineralys Therapeutics (MLYS) | 1.8 | $11M | +83% | 290k | 36.29 |
|
| Madrigal Pharmaceuticals (MDGL) | 1.7 | $10M | +116% | 18k | 582.34 |
|
| Adaptive Biotechnologies Cor (ADPT) | 1.6 | $9.9M | NEW | 607k | 16.24 |
|
| Palisade Bio (PALI) | 1.6 | $9.9M | NEW | 4.2M | 2.35 |
|
| Cytokinetics Com New (CYTK) | 1.6 | $9.3M | NEW | 147k | 63.54 |
|
| Edgewise Therapeutics (EWTX) | 1.5 | $9.0M | NEW | 361k | 24.82 |
|
| Bright Minds Biosciences Com New (DRUG) | 1.3 | $7.6M | NEW | 97k | 78.04 |
|
| Nektar Therapeutics Com New (NKTR) | 1.3 | $7.5M | +235% | 178k | 42.28 |
|
| Johnson & Johnson (JNJ) | 1.2 | $7.2M | NEW | 35k | 206.95 |
|
| Denali Therapeutics (DNLI) | 1.2 | $6.9M | -75% | 419k | 16.51 |
|
| Amylyx Pharmaceuticals (AMLX) | 1.1 | $6.8M | +104% | 565k | 12.08 |
|
| Clearpoint Neuro (CLPT) | 1.1 | $6.6M | +2793% | 482k | 13.68 |
|
| Arcutis Biotherapeutics (ARQT) | 1.1 | $6.5M | -45% | 225k | 29.04 |
|
| Eyepoint Com New (EYPT) | 1.1 | $6.5M | NEW | 354k | 18.27 |
|
| Immatics SHS (IMTX) | 1.1 | $6.4M | NEW | 610k | 10.50 |
|
| Ocular Therapeutix (OCUL) | 1.1 | $6.3M | +45% | 523k | 12.14 |
|
| Rhythm Pharmaceuticals (RYTM) | 1.1 | $6.3M | -35% | 59k | 107.04 |
|
| Praxis Precision Medicines I Com New (PRAX) | 1.0 | $6.2M | NEW | 21k | 294.74 |
|
| Apogee Therapeutics (APGE) | 1.0 | $6.1M | NEW | 81k | 75.48 |
|
| Incyte Corporation (INCY) | 1.0 | $6.1M | +40% | 61k | 98.77 |
|
| Ideaya Biosciences (IDYA) | 0.9 | $5.6M | -56% | 162k | 34.57 |
|
| Assembly Biosciences Com New (ASMB) | 0.9 | $5.3M | +136% | 157k | 34.01 |
|
| Maze Therapeatics (MAZE) | 0.9 | $5.2M | NEW | 126k | 41.43 |
|
| Protagonist Therapeutics (PTGX) | 0.9 | $5.2M | +23% | 59k | 87.34 |
|
| Eli Lilly & Co. (LLY) | 0.9 | $5.1M | NEW | 4.8k | 1074.68 |
|
| Trevi Therapeutics (TRVI) | 0.8 | $5.0M | +13% | 400k | 12.52 |
|
| Revolution Medicines (RVMD) | 0.8 | $4.9M | -66% | 62k | 79.65 |
|
| Miragen Therapeutics (VRDN) | 0.8 | $4.8M | NEW | 154k | 31.12 |
|
| Arbutus Biopharma (ABUS) | 0.8 | $4.7M | +228% | 987k | 4.81 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.8 | $4.6M | NEW | 348k | 13.18 |
|
| Cytomx Therapeutics (CTMX) | 0.7 | $4.4M | NEW | 1.0M | 4.26 |
|
| X4 Pharmaceuticals Com New (XFOR) | 0.6 | $3.6M | +61% | 899k | 4.00 |
|
| Aadi Bioscience (WHWK) | 0.6 | $3.5M | +243% | 1.5M | 2.42 |
|
| Dianthus Therapeutics (DNTH) | 0.5 | $3.3M | +91% | 79k | 41.21 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.5 | $3.2M | -2% | 15k | 213.24 |
|
| Repligen Corporation (RGEN) | 0.4 | $2.6M | NEW | 16k | 163.86 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.4 | $2.6M | -51% | 73k | 35.08 |
|
| Mbx Biosciences (MBX) | 0.4 | $2.5M | +4% | 79k | 31.54 |
|
| Cortexyme (QNCX) | 0.4 | $2.5M | NEW | 739k | 3.35 |
|
| Avalo Therapeutics Com New (AVTX) | 0.4 | $2.5M | NEW | 136k | 18.16 |
|
| Adagio Therapeutics (IVVD) | 0.4 | $2.4M | +255% | 990k | 2.47 |
|
| Meiragtx Holdings (MGTX) | 0.4 | $2.3M | +251% | 288k | 7.95 |
|
| Inventiva Sa Ads (IVA) | 0.4 | $2.2M | +1415% | 467k | 4.65 |
|
| Abbvie (ABBV) | 0.4 | $2.1M | NEW | 9.3k | 228.49 |
|
| Adc Therapeutics Sa SHS (ADCT) | 0.3 | $1.8M | +77% | 503k | 3.53 |
|
| Maplight Therapeutics (MPLT) | 0.3 | $1.8M | NEW | 100k | 17.57 |
|
| Pharvaris N V (PHVS) | 0.3 | $1.6M | NEW | 58k | 27.75 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 0.3 | $1.6M | NEW | 73k | 21.74 |
|
| Belite Bio Sponsored Ads (BLTE) | 0.2 | $1.5M | NEW | 9.2k | 159.96 |
|
| Xilio Therapeutics (XLO) | 0.2 | $1.3M | NEW | 2.0M | 0.64 |
|
| Evommune Com Shs (EVMN) | 0.2 | $1.2M | NEW | 68k | 17.12 |
|
| Bridgebio Oncology Therapeut Com New (BBOT) | 0.2 | $1.1M | -53% | 87k | 12.52 |
|
| Spyre Therapeutics Com New (SYRE) | 0.2 | $1.1M | NEW | 32k | 32.76 |
|
| Uniqure Nv SHS (QURE) | 0.2 | $1.0M | -91% | 44k | 23.93 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.2 | $1.0M | -78% | 182k | 5.50 |
|
| Monte Rosa Therapeutics (GLUE) | 0.2 | $966k | NEW | 62k | 15.68 |
|
| Sab Biotherapeutics Com New (SABS) | 0.1 | $548k | NEW | 147k | 3.74 |
|
| Vanda Pharmaceuticals (VNDA) | 0.1 | $520k | NEW | 59k | 8.82 |
|
| Capricor Therapeutics Com New (CAPR) | 0.1 | $515k | NEW | 18k | 28.86 |
|
| Pasithea Therapeutics Corp Com New (KTTA) | 0.1 | $458k | NEW | 355k | 1.29 |
|
| Vistagen Therapeutics Ord (VTGN) | 0.0 | $142k | -75% | 617k | 0.23 |
|
Past Filings by Stempoint Capital
SEC 13F filings are viewable for Stempoint Capital going back to 2024
- Stempoint Capital 2025 Q4 filed Feb. 17, 2026
- Stempoint Capital 2025 Q3 filed Nov. 14, 2025
- Stempoint Capital 2025 Q2 filed Aug. 14, 2025
- Stempoint Capital 2025 Q1 filed May 15, 2025
- Stempoint Capital 2024 Q4 filed Feb. 14, 2025
- Stempoint Capital 2024 Q3 filed Nov. 13, 2024
- Stempoint Capital 2024 Q2 restated filed Aug. 13, 2024
- Stempoint Capital 2024 Q1 restated filed Aug. 9, 2024